Fasentin

Non disponible en dehors du Royaume-Uni et de l'Irlande

General description

A cell-permeable oxobutananilide compound that is predicted to interact with Glut (Glucose Transporter) at an intracellular site based on a virtual docking study and shown to inhibit Glut-mediated cellular glucose uptake (50% and 80% inhibition of 2-deoxy-D-glucose uptake in Glut1- and Glut4-overexpressing L6 myoblasts, respectively, at 300 µM). Fas-resistant cell lines that are made Fas-responsive upon medium glucose deprivation are also shown to be sensitized by Fasentin to Fas-mediated cell death (ED₅₀ = 35 µM in PPC-1 cultures), while cells that remain Fas-resistant upon glucose deprivation, e.g. DU145, are shown not to be sensitized by Fasentin to Fas-mediated death.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Wood, T.E., et al. 2008. Mol. Cancer Ther.7, 3546Schimmer, A.D., et al. 2006. Cancer Res.66, 2367.

Packaging

Packaged under inert gas

25 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -2°C.

Warning

Toxicity: Standard Handling (A)